Logo image of CLOV

CLOVER HEALTH INVESTMENTS CO (CLOV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLOV - US18914F1030 - Common Stock

2.64 USD
+0.02 (+0.76%)
Last: 12/16/2025, 8:09:42 PM
2.63 USD
-0.01 (-0.38%)
Pre-Market: 12/17/2025, 7:36:54 AM
Fundamental Rating

2

Overall CLOV gets a fundamental rating of 2 out of 10. We evaluated CLOV against 100 industry peers in the Health Care Providers & Services industry. While CLOV seems to be doing ok healthwise, there are quite some concerns on its profitability. CLOV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLOV has reported negative net income.
CLOV had a negative operating cash flow in the past year.
CLOV had negative earnings in each of the past 5 years.
In the past 5 years CLOV reported 4 times negative operating cash flow.
CLOV Yearly Net Income VS EBIT VS OCF VS FCFCLOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

CLOV has a Return On Assets of -10.40%. This is in the lower half of the industry: CLOV underperforms 74.00% of its industry peers.
Looking at the Return On Equity, with a value of -17.08%, CLOV is doing worse than 64.00% of the companies in the same industry.
Industry RankSector Rank
ROA -10.4%
ROE -17.08%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-29.85%
ROE(3y)-60.71%
ROE(5y)-58.55%
ROIC(3y)N/A
ROIC(5y)N/A
CLOV Yearly ROA, ROE, ROICCLOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLOV Yearly Profit, Operating, Gross MarginsCLOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

5

2. Health

2.1 Basic Checks

CLOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLOV has more shares outstanding
CLOV has more shares outstanding than it did 5 years ago.
CLOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLOV Yearly Shares OutstandingCLOV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
CLOV Yearly Total Debt VS Total AssetsCLOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.27, we must say that CLOV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.27, CLOV is doing worse than 69.00% of the companies in the same industry.
There is no outstanding debt for CLOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACCN/A
WACC8.82%
CLOV Yearly LT Debt VS Equity VS FCFCLOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.71 indicates that CLOV should not have too much problems paying its short term obligations.
The Current ratio of CLOV (1.71) is better than 66.00% of its industry peers.
A Quick Ratio of 1.71 indicates that CLOV should not have too much problems paying its short term obligations.
The Quick ratio of CLOV (1.71) is better than 71.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
CLOV Yearly Current Assets VS Current LiabilitesCLOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CLOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.11%, which is quite impressive.
CLOV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.84%.
CLOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.34% yearly.
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
Revenue 1Y (TTM)14.84%
Revenue growth 3Y-2.34%
Revenue growth 5YN/A
Sales Q2Q%50.05%

3.2 Future

The Earnings Per Share is expected to grow by 40.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.46% on average over the next years. This is quite good.
EPS Next Y-96.44%
EPS Next 2Y30.3%
EPS Next 3Y33.82%
EPS Next 5Y40.11%
Revenue Next Year25.45%
Revenue Next 2Y31.43%
Revenue Next 3Y25.37%
Revenue Next 5Y19.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLOV Yearly Revenue VS EstimatesCLOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
CLOV Yearly EPS VS EstimatesCLOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLOV Price Earnings VS Forward Price EarningsCLOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLOV Per share dataCLOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

CLOV's earnings are expected to grow with 33.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.3%
EPS Next 3Y33.82%

More info and screens

0

5. Dividend

5.1 Amount

CLOV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CLOVER HEALTH INVESTMENTS CO

NASDAQ:CLOV (12/16/2025, 8:09:42 PM)

Premarket: 2.63 -0.01 (-0.38%)

2.64

+0.02 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners32.29%
Inst Owner Change-7.48%
Ins Owners2.71%
Ins Owner Change-4.74%
Market Cap1.36B
Revenue(TTM)1.77B
Net Income(TTM)-58.23M
Analysts77.78
Price Target3.3 (25%)
Short Float %9.97%
Short Ratio4.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.35%
Min EPS beat(2)-63.4%
Max EPS beat(2)28.7%
EPS beat(4)3
Avg EPS beat(4)26.24%
Min EPS beat(4)-63.4%
Max EPS beat(4)100%
EPS beat(8)7
Avg EPS beat(8)40.42%
EPS beat(12)11
Avg EPS beat(12)37.49%
EPS beat(16)13
Avg EPS beat(16)31.61%
Revenue beat(2)1
Avg Revenue beat(2)1.68%
Min Revenue beat(2)-0.01%
Max Revenue beat(2)3.36%
Revenue beat(4)1
Avg Revenue beat(4)-3.94%
Min Revenue beat(4)-13.64%
Max Revenue beat(4)3.36%
Revenue beat(8)4
Avg Revenue beat(8)-1.11%
Revenue beat(12)7
Avg Revenue beat(12)0.43%
Revenue beat(16)11
Avg Revenue beat(16)1.55%
PT rev (1m)-3.96%
PT rev (3m)-11.42%
EPS NQ rev (1m)-54.99%
EPS NQ rev (3m)-87.87%
EPS NY rev (1m)-62.49%
EPS NY rev (3m)-44.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.23%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 4
P/tB 4.04
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS3.43
BVpS0.66
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.4%
ROE -17.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-29.85%
ROE(3y)-60.71%
ROE(5y)-58.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover3.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.96%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.27
F-Score6
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)171.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
EPS Next Y-96.44%
EPS Next 2Y30.3%
EPS Next 3Y33.82%
EPS Next 5Y40.11%
Revenue 1Y (TTM)14.84%
Revenue growth 3Y-2.34%
Revenue growth 5YN/A
Sales Q2Q%50.05%
Revenue Next Year25.45%
Revenue Next 2Y31.43%
Revenue Next 3Y25.37%
Revenue Next 5Y19.46%
EBIT growth 1Y20.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.99%
EBIT Next 3Y50.13%
EBIT Next 5YN/A
FCF growth 1Y13.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.59%
OCF growth 3YN/A
OCF growth 5YN/A

CLOVER HEALTH INVESTMENTS CO / CLOV FAQ

What is the ChartMill fundamental rating of CLOVER HEALTH INVESTMENTS CO (CLOV) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLOV.


What is the valuation status of CLOVER HEALTH INVESTMENTS CO (CLOV) stock?

ChartMill assigns a valuation rating of 1 / 10 to CLOVER HEALTH INVESTMENTS CO (CLOV). This can be considered as Overvalued.


What is the profitability of CLOV stock?

CLOVER HEALTH INVESTMENTS CO (CLOV) has a profitability rating of 0 / 10.